Data from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can potentially ameliorate ineffective hematopoiesis and address cytopenias, and also provide broader ...
Antengene Corporation Limited Antengene SEHK 6996HK a leading innovative commercial-stage global biopharmaceutical company dedicated to discovering developing and commercializing first-in-class andor ...
Regeneron (REGN) announced new and updated data for odronextamab were presented at the 66th American Society of Hematology, or ASH, annual ...
Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) ...
Southlake Regional Health Centre’s Dr. Kevin Teoh is a leading cardiac surgeon. He implanted the first Perceval valve in ...
AFM28, a bispecific, tetravalent innate cell engager (ICE ®) targeting CD123 and CD16A, achieved a 40% composite complete ...
N.V. announced the oral presentation of data on AFM28 at the 66th ASH Annual Meeting and Exposition. The data, derived from the ...
Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, ...
Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...
Cogent Biosciences' SUMMIT trial shows bezuclastinib improves symptoms and quality of life in systemic mastocytosis, with ...
The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...
The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...